Literature DB >> 22618509

miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes.

Yong-Kui Zhang1, Wang-Yu Zhu, Jian-Ying He, Dong-Dong Chen, Yan-Yan Huang, Han-Bo Le, Xiao-Guang Liu.   

Abstract

PURPOSE: We investigated whether miRNA expression profiles can distinguish and predict outcome of non-small-cell lung carcinoma (NSCLC) patients with different histological subtypes.
METHODS: High-throughput microarray was used to measure miRNA expression levels in six NSCLC samples. Subsequently, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to verify findings in an independent set of 54 squamous-cell lung carcinomas (SCC), 51 lung adenocarcinomas (AD), and paired adjacent non-neoplastic lung tissue.
RESULTS: We showed that, compared to adjacent non-neoplastic lung tissues, the expressions of miR-125a-5p and let-7e were decreased in AD and SCC samples, while increased expressions of miR-93, miR-205, and miR-221 were observed in SCC samples. In addition, miR-205 expression was significantly higher in SCC patients with lymph node metastasis. Lower let-7e expression was associated with lymph node metastasis, >3 cm tumor size, and differentiation of the NSCLC AD subtype. High levels of miR-100 expression also correlated with the AD subtype in current smokers. Moreover, induction of miR-93 and miR-205 expressions and reduction of let-7e were strongly associated with shorter overall survival in SCC patients, whereas AD patient survival was only associated with reduced let-7e.
CONCLUSIONS: We identified differential expression profiles of miRNAs in AD and SCC. More importantly, in addition to morphology and immunocytochemistry approaches, we report that miR-93, miR-205, miR-221, and let-7e may represent novel biomarkers for differential diagnosis and prognosis of certain NSCLC subtypes or be new targets of histology-specific treatments. Furthermore, our results suggest a strong correlation between high expression of miR-100 and AD patients with history of heavy smoking.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22618509     DOI: 10.1007/s00432-012-1240-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease.

Authors:  Geert R Van Pottelberge; Pieter Mestdagh; Ken R Bracke; Olivier Thas; Yannick M T A van Durme; Guy F Joos; Jo Vandesompele; Guy G Brusselle
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 3.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

4.  Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.

Authors:  Marco Ragusa; Alessandra Majorana; Luisa Statello; Marco Maugeri; Loredana Salito; Davide Barbagallo; Maria Rosa Guglielmino; Laura R Duro; Rosario Angelica; Rosario Caltabiano; Antonio Biondi; Maria Di Vita; Giuseppe Privitera; Marina Scalia; Alessandro Cappellani; Enrico Vasquez; Salvatore Lanzafame; Francesco Basile; Cinzia Di Pietro; Michele Purrello
Journal:  Mol Cancer Ther       Date:  2010-09-29       Impact factor: 6.261

5.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

6.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 10.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

View more
  28 in total

Review 1.  MicroRNAs in lung cancer.

Authors:  Pooja Joshi; Justin Middleton; Young-Jun Jeon; Michela Garofalo
Journal:  World J Methodol       Date:  2014-06-26

2.  MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Authors:  Santosh Patnaik; Reema Mallick; Eric Kannisto; Rohit Sharma; Wiam Bshara; Sai Yendamuri; Samjot Singh Dhillon
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

Review 3.  miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC).

Authors:  Yichao Han; Hecheng Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  miR-93 promotes TGF-β-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells.

Authors:  Mei-Hua Qu; Chunhua Han; Amit Kumar Srivastava; Tiantian Cui; Ning Zou; Zhi-Qin Gao; Qi-En Wang
Journal:  Tumour Biol       Date:  2015-11-18

5.  Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma.

Authors:  Guo Li; Shuling Ren; Zhongwu Su; Chao Liu; Tengbo Deng; Donghai Huang; Yongquan Tian; Yuanzheng Qiu; Yong Liu
Journal:  Tumour Biol       Date:  2015-01-13

6.  Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma.

Authors:  Tao Huang; Jing Yang; Yu-Dong Cai
Journal:  Biomed Res Int       Date:  2015-02-23       Impact factor: 3.411

Review 7.  Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies.

Authors:  Jia-Yi Zhang; Meng-Yan Sun; Ning-Hong Song; Zhong-Lei Deng; Chun-Yu Xue; Jie Yang
Journal:  BMJ Open       Date:  2015-01-22       Impact factor: 2.692

8.  Smoking status impacts microRNA mediated prognosis and lung adenocarcinoma biology.

Authors:  Emily A Vucic; Kelsie L Thu; Larissa A Pikor; Katey S S Enfield; John Yee; John C English; Calum E MacAulay; Stephen Lam; Igor Jurisica; Wan L Lam
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

9.  miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1.

Authors:  Yang Ke; Weiyong Zhao; Jie Xiong; Rubo Cao
Journal:  Biochem Res Int       Date:  2013-05-16

10.  The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases.

Authors:  Petra Leidinger; Christina Backes; Michael Blatt; Andreas Keller; Hanno Huwer; Philipp Lepper; Robert Bals; Eckart Meese
Journal:  Mol Cancer       Date:  2014-08-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.